













# LEO Pharma pipeline overview

## 2023/Q2

| Project*                                    | Description                                                                                                                     | Partners                                                                            | Pre-clinical                                                                          | Phase 1 | Phase 2 | Phase 3 | Registration |
|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------|---------|---------|--------------|
| <b>Delgocitinib</b><br>LP0133               | A pan-JAK inhibitor under development for topical use in patients with chronic hand eczema and / or frontal fibrosing alopecia. |  |    |         |         |         |              |
| <b>Anti IL-22R</b><br>LP0145                | An IL-22 receptor antagonist under development for use in patients with atopic dermatitis.                                      |  |    |         |         |         |              |
| <b>Izuforant</b><br>LP0190                  | A histamine 4 receptor (H4R) antagonist under development for use in patients with atopic dermatitis.                           |  |    |         |         |         |              |
| <b>Anti IgE<sup>+</sup>B-cell</b><br>LP0201 | A monoclonal antibody for use in patients with allergic asthma.                                                                 |  |    |         |         |         |              |
| <b>LEO 158968</b><br>LP0189                 | A monoclonal antibody under development for the treatment of anti-inflammatory skin diseases.                                   |  |    |         |         |         |              |
| <b>IL-17 PPI<sub>m</sub></b><br>LP0128      | An IL-17 PPI modulator                                                                                                          |                                                                                     |  |         |         |         |              |

\*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.



All LEO Pharma trademarks belong to the LEO Pharma Group

© 2023 LEO Pharma A/S. All rights reserved. MAT-66539 June 2023